UPMC Health Plan reaches deal with pharmaceutical company for MS medications

UPMC Health Plan has reached a deal with a pharmaceutical company that will link reimbursement for two medications for multiple sclerosis to patient outcomes. Financial terms of the deal between UPMC Health Plan and Biogen (Nasdaq: BIIB) for Tecfidera and Avonex weren't announced. But this value-based agreement, the first of its kind, provides for reimbursement based on how well the drug keeps patients from further disability. Previous contracts have be en tied to health records and claims data. Yet…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news